ANDOVER, Mass., Dec. 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, January 11, 2023, at 5:15 p.m. Pacific Standard Time / 8:15 p.m. Eastern Standard Time.
Event: 41st Annual J.P. Morgan Healthcare Conference
Date: Wednesday, January 11, 2023
Time: 5:15 p.m. PST
A live and archived webcast of the presentation will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
332-895-3222
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$117.38 |
Daily Change: | 2.20 1.91 |
Daily Volume: | 598,148 |
Market Cap: | US$4.000B |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load